Michael Savona, MD
Dr. Savona is an internationally renowned clinician-physician-scientist specializing in myeloid malignancies, and a leader in development of novel therapies for these patients. He has led development of over 20 approved therapies in hematologic malignancies, and responsible for patents for new therapies currently under development. Dr. Savona founded the MDS/MPN International Working Group in 2011 and leads an international platform study of novel therapies in MDS/MPN overlap syndromes. He is an elected fellow of the American College of Physicians, and American Association for Advancement of Science, and volunteers on the board of directors for the MDS Foundation. He also served as physician in the United States Air Force and is a veteran of Operation Enduring Freedom/Operation Iraqi Freedom.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:MDSF FoundationTopic:Leadership RoleDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Financial StakeIneligible company:Karyopharm TherapueticsTopic:Stock and Other Ownership InteresDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Financial StakeIneligible company:Empath BiosciencesTopic:Stock and Other Ownership InteresDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Financial StakeIneligible company:Ryvu TherapeuticsTopic:Stock and Other Ownership InteresDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:RyvuTopic:Consulting or Advisory RoleDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Bristol-Myers SquibTopic:Consulting or Advisory RoleDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PharmaessentiaTopic:Consulting or Advisory RoleDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:CalytrixTopic:Consulting or Advisory RoleDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GeronTopic:Consulting or Advisory RoleDate added:02/19/2026Date updated:02/19/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:RigelTopic:Consulting or Advisory RoleDate added:02/19/2026Date updated:02/19/2026

Facebook
X
LinkedIn
Forward